Sepsis biomarkers: a review.
Pierrakos C, Vincent JL. · 2010
Read Sepsis biomarkers: a review. by Pierrakos C, Vincent JL. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2875530.txt.
Introduction
Pierrakos and Vincent reviewed in 2010 the blood markers proposed for sepsis, the body's runaway response to infection that can kill within days. A good marker could confirm sepsis early, rule it out, pick who benefits from a therapy, or show whether treatment works. The pair searched the medical database for studies testing any marker in sepsis.
Their search surfaced over three thousand papers covering one hundred seventy-eight different markers. Most had been tried as outlook predictors rather than as diagnostic tests. None proved sharp enough for routine use, since each missed cases or fired falsely in other inflammatory states. The two most used markers, procalcitonin and C-reactive protein, still could not reliably separate sepsis from sterile inflammation or forecast a patient's course.
Catalog record
| CREATOR | Pierrakos C, Vincent JL. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Sepsis biomarkers: a review By Charalampos Pierrakos, Jean-Louis Vincent Published in: Critical Care DOI: 10.1186/cc8872 ABSTRACT Abstract Introduction Biomarkers can be useful for identifying or ruling out sepsis, identifying patients who may benefit from specific therapies or assessing the response to therapy. Methods We used an electronic search of the PubMed database using the key words "sepsis" and "biomarker" to identify clinical and experimental studies which evaluated a biomarker in sepsis. Results The search retrieved 3370 references covering 178 different biomarkers. Conclusions Many biomarkers have been evaluated for use in sepsis. Most of the biomarkers had been tested clinically, primarily as prognostic markers in sepsis; relatively few have been used for diagnosis. None has sufficient specificity or sensitivity to be routinely employed in clinical practice. PCT and CRP have been most widely used, but even these have limited ability to distinguish sepsis from other inflammatory conditions or to predict outcome. INTRODUCTION Sepsis is a leading cause of death in critically ill patients despite the use of modern antibiotics and resuscitation therapies [1]. The septic response is an extremely complex chain of events involving inflammatory and anti-inflammatory processes, humoral and cellular reactions and circulatory abnormalities [2,3]. The diagnosis of sepsis and evaluation of its severity is complicated by the highly variable and non-specific nature of the signs and symptoms of sepsis [4]. However, the early diagnosis and stratification of the severity of sepsis is very important, increasing the possibility of starting timely and specific treatment [5,6]. Biomarkers can have an important place in this process because they can indicate the presence or absence or severity of sepsis [7,8], and can differentiate bacterial from viral and fungal infection, and systemic sepsis from local infection. Other potential uses of biomarkers include roles in prognostication, guiding antibiotic therapy, evaluating the response to therapy and recovery from sepsis, differentiating Gram-positive from Gram-negative microorganisms as the cause of sepsis, predicting sepsis complications and the development of organ dysfunction (heart, kidneys, liver or multiple organ dysfunction). However, the exact role of biomarkers in the management of septic patients remains undefined [9]. C-reactive protein (CRP) has been used for many years [10,11] but its specificity has been challenged [12]. Procalcitonin (PCT) has been proposed as a more specific [13] and better prognostic [14] marker than CRP, although its value has also been challenged [15]. It remains difficult to differentiate sepsis from other non-infectious causes of systemic inflammatory response syndrome [16], and there is a continuous search for better biomarkers of sepsis. With this background in mind, we reviewed the literature on sepsis biomarkers that have been used in clinical or experimental studies to help better evaluate their utility. MATERIALS AND METHODS The entire Medline database was searched in February 2009 using the key words 'sepsis' and 'biomarker'. All studies, both clinical and experimental, which evaluated a biomarker were included. For each identified biomarker, the Medline database was searched again using the biomarker name and the key word 'biomarker'. RESULTS A total of 3370 studies that assessed a biomarker in sepsis were retrieved; 178 different biomarkers were evaluated in the 3370 studies. The retrieved biomarkers and the major findings from key studies using these biomarkers are listed in Tables 1, 2, 3, 4, 5, 6, 7, 8 and 9. Of the 178 biomarkers, 18 had been evaluated in experimental studies only, 58 in both experimental and clinical studies, and 101 in clinical studies only. Thirty-four biomarkers were identified that have been assessed for use specifically in the diagnosis of sepsis (Table 10); of these just five reported sensitivity and specificity values greater than 90%. [Table: Cytokine/chemokine biomarkers identified in the literature search (with some selected references)] [Table: Cell marker biomarkers identified in the literature search (with some selected references)] [Table: Receptor biomarkers identified in the literature search (with some selected references)] [Table: Coagulation biomarkers identified in the literature search (with some selected references)] [Table: Biomarkers related to vascular endothelial damage identified in the literature search (with some selected references)] [Table: Biomarkers related to vaosdilation identified in the literature search (with some selected references)] [Table: Biomarkers of organ dysfunction identified in the literature search (with some selected references)] [Table: Acute phase protein biomarkers identified in the literature search (with some selected references)] [Table: Other biomarkers identified in the literature search (with some selected references)] [Table: Biomarkers that have been assessed for use in the diagnosis of sepsis] DISCUSSION A multitude of biomarkers has been proposed in the field of sepsis, many more than in other disease processes; for example, a study of patients with myocardial infarction revealed 14 biomarkers suitable for diagnosis and determination of prognosis [17] and in patients with Alzheimer's disease, just 8 biomarkers were identified [18]. This large difference in the numbers of biomarkers for sepsis is likely to be related to the very complex pathophysiology of sepsis, which involves many mediators of inflammation [19], but also other pathophysiological mechanisms. Coagulation, complement, contact system activation, inflammation, and apoptosis are all involved in the sepsis process, and separate markers for each (part of each) system have been proposed (Tables 1 to 9). Additionally, the systemic nature of sepsis and the large numbers of cell types, tissues and organs involved expand the number of potential biomarker candidates, compared with disease processes that involve individual organs or are more localized. It is interesting to note that most of the biomarkers we identified have been tested clinically and not experimentally. This is likely to be in part related to difficulties creating an experimental model that accurately reflects all aspects of human sepsis, problems with species differences, and problems in determining end-points in animal studies. Additionally, as the sepsis response varies with time, the exact time period during which any specific biomarker may be useful varies, and this is difficult to assess reliably in experimental models. Moreover, as there is no 'gold standard' for the diagnosis of sepsis, the effectiveness of a biomarker needs to be compared with current methods used to diagnose and monitor sepsis in everyday clinical practice, i.e., by the combination of clinical signs and available laboratory variables [20]; experimental models cannot be used for this purpose. Our study revealed that there are many more potential biomarkers for sepsis than are currently used in clinical studies. Some of these markers may require considerable time, effort and costs to measure. Some are already routinely used for other purposes and easily obtained, such as coagulation tests or cholesterol concentrations. In many cases, the reliability and validity of the proposed biomarker have not been tested properly [8]. Of the many proposed markers for sepsis, acute phase proteins have perhaps been most widely assessed. PCT has been used particularly extensively in recent years. The specificity and sensitivity of PCT for the diagnosis of sepsis is relatively low (typically below 90%), regardless of the cut-off value [21,22]. Raised PCT levels have also been reported in other conditions associated with inflammatory response, such as trauma [23], major surgery [24] and cardiac surgery [25]. Although CRP is often reported as inferior compared with PCT in terms of sepsis diagnosis, it is frequently used in clinical practice because of its greater availability. Elevated concentrations of serum CRP are correlated with an increased risk of organ failure and